US children as young as 8 prescribed off‑label GLP‑1 weight‑loss drugs

In recent months, pediatric physicians across the United States have begun prescribing glucagon‑like peptide‑1 (GLP‑1) receptor agonists—medications originally approved for adult type 2 diabetes and, more recently, for adult obesity—to children as young as eight years old. The drugs, marketed under names such as semaglutide (Wegovy) and liraglutide (Saxenda), are being used off‑label to curb severe obesity in minors, a practice that has drawn attention from medical societies, regulators, and parent groups. According to data from a national pharmacy‑claims database, the number of pediatric GLP‑1 prescriptions rose sharply in 2023, coinciding with broader concerns about rising childhood obesity rates and limited non‑pharmacologic treatment options.

Health professionals caution that the long‑term safety profile of GLP‑1 agonists in children remains largely unstudied. The U.S. Food and Drug Administration has not approved any GLP‑1 drug for pediatric weight management, and its labeling advises against off‑label use without robust clinical evidence. Pediatric endocrinologists highlight potential risks such as gastrointestinal disturbances, altered growth patterns, and unknown metabolic effects that could emerge over years of exposure. At the same time, some clinicians argue that the immediate benefits—significant weight reduction and improvement in obesity‑related comorbidities—may outweigh the uncertain long‑term risks for severely affected youth.

The growing off‑label use has sparked a debate over the balance between urgent therapeutic need and the paucity of pediatric data. Medical societies are calling for controlled trials to assess efficacy and safety in children, while insurers and policymakers consider how to address coverage and regulatory oversight. As the discussion continues, physicians are urged to weigh individual patient circumstances carefully and to monitor outcomes closely pending further research.